OTC · Medical - Pharmaceuticals

Dechra Pharmaceuticals PLC (DCHPF) Stock

$46.90 -0.21% OTC: DCHPF Healthcare

Dechra Pharmaceuticals PLC specializes in the entire lifecycle of veterinary products, from development and manufacturing to regulatory approval, marketing, and sales, primarily serving veterinarians. The company's operations are structured across three main divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development.

Valuation

MetricValue
Price$46.90
Market Cap$5.34B
P/E Ratio-161.08
P/B Ratio5.81
P/S Ratio5.78
EPS (TTM)$-0.24
52-Week High$47.40
52-Week Low$30.00
Dividend Yield0.32%

Financials & Margins

MetricValue
ROE-3.92%
ROA-1.78%
ROCE0.45%
Gross Margin55.98%
Operating Margin0.83%
Net Margin-3.66%
Debt/Equity0.67
Current Ratio2.85

Annual Financials (USD)

Metric20182019202020212022
Revenue$482.0M$515.0M$608.0M$682.0M$762.0M
Operating Profit$51.0M$59.0M$87.0M$96.0M$6.0M
Net Profit$31.0M$34.0M$56.0M$58.0M$-28.0M
EPS$0.30$0.33$0.51$0.53$-0.24
Op Margin10.5%11.4%14.3%14.0%0.8%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$1.0B$1.2B$1.2B$1.3B$1.6B
Total Liabilities$539.0M$600.0M$581.0M$627.0M$814.0M
Cash$80.0M$227.0M$118.0M$121.0M$74.0M
Borrowings$308.0M$355.0M$319.0M$329.0M$505.0M

Latest News

Boeing Delivered 64 Jets in June. Here's What That Means for Its July 28 Earnings. Motley Fool · Jul 16, 2026 Netflix shares drop on growth worries AFP · Jul 16, 2026 Constellation Software Inc. Announces Conference Call to Discuss Second Quarter Results GlobeNewswire · Jul 16, 2026 Ola-Ola brand Authentic Pounded Yam (Iyan) IYANINSTANT recalled due to undeclared milk CNW Group · Jul 16, 2026 FormFactor and Kulicke and Soffa Shares Are Falling, What You Need To Know StockStory · Jul 16, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$82.0M$106.0M$89.0M$123.0M$64.0M
Investing Cash Flow$-84.0M$-131.0M$-155.0M$-156.0M$-456.0M
Financing Cash Flow$44.0M$292.0M$-17.0M$2.0M$353.0M
Net Cash Flow$1.0M$147.0M$-109.0M$3.0M$-46.0M
Free Cash Flow$59.0M$57.0M$70.0M$45.0M$33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.61
EV / EBITDA55.75
FCF Yield0.76%
Quick Ratio1.53
Interest Coverage0.14
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC specializes in the entire lifecycle of veterinary products, from development and manufacturing to regulatory approval, marketing, and sales, primarily serving veterinarians. The company's operations are structured across three main divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. Their extensive product portfolio addresses a diverse array of animal health needs. For companion animals such as dogs and cats, they offer treatments for endocrinological and dermatological conditions, pain relief and anesthesia, cardiovascular issues, and critical care, alongside specialized therapeutic pet nutrition to manage allergies, obesity, and heart or kidney diseases. For livestock including poultry, pigs, and cattle, Dechra provides water-soluble antibiotics, vaccines, and pain management solutions. Equine care products focus on addressing lameness and pain in horses and ponies. Beyond core pharmaceuticals, the company also distributes veterinary equipment, offers financial services, markets various pet diets, and surprisingly, is involved in the development, regulation, manufacture, and commercialization of crop protection products. Dechra's offerings reach the market through robust wholesaler and distributor networks. Incorporated in 1997 and based in Northwich, United Kingdom, the company maintains a significant international presence, operating across the UK, Germany, wider Europe, the United States, and other global territories.

Dechra Pharmaceuticals PLC is headquartered in GB.

Dechra Pharmaceuticals PLC (DCHPF) stock trades at $46.90 with a market capitalization of $5.34B. The stock is valued at a price-to-earnings (P/E) ratio of -161.08, price-to-book of 5.81, price-to-sales of 5.78. Over the past 52 weeks the stock has ranged between $30.00 and $47.40, and currently trades 1.1% below its 52-week high. It pays a dividend yielding 0.32%.

On profitability, Dechra Pharmaceuticals PLC generates a return on equity (ROE) of -3.92%, return on capital employed of 0.45%, an operating margin of 0.83%, a net profit margin of -3.66%.

Official website: www.dechra.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides